Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03472014 · ClinicalTrials.gov registry record · Phase 4
Special Access Program IMVAMUNE®
A Phase 4 study of Vaccination, sponsored by Bavarian Nordic.
- Completed
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT03472014: Completed Phase 4 study of Vaccination, sponsored by Bavarian Nordic.
NCT03472014 is a Phase 4 study of Vaccination that has completed, run by Bavarian Nordic. The registered enrollment target is 22 participants, below the 10,232-participant average among 12 other Vaccination trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03472014, a Phase 4 study of Vaccination, has completed, sponsored by Bavarian Nordic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
Prophylactic smallpox vaccination for personnel actively working with or in the vicinity of replicating vaccinia virus
Primary Outcome
Seropositivity rate based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Seropositivity is defined as antibody titers ≥ detection limit (50). Percentages based on number of subjects with data available.
Conditions Studied
Interventions
- BIOLOGICAL IMVAMUNE®
Study Locations (1)
California
- Palo Alto Medical Foundation - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2010-04-22 |
| Est. Completion | 2014-11-14 |
| Phase | Phase 4 |
What the finished NCT03472014 record still lists
NCT03472014 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 10,232-participant average among 12 other Vaccination trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Vaccination appearing as the primary indexed condition, and to 1 intervention - of which IMVAMUNE® is the first listed.
NCT03472014 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03472014 about?
NCT03472014 is a clinical study titled "Special Access Program IMVAMUNE®". Prophylactic smallpox vaccination for personnel actively working with or in the vicinity of replicating vaccinia virus
What is the current status of trial NCT03472014?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2010-04-22. Estimated completion is 2014-11-14.
What conditions does trial NCT03472014 study?
This clinical trial studies the following conditions: Vaccination.
What interventions are being tested in trial NCT03472014?
The interventions under investigation include: IMVAMUNE® (BIOLOGICAL).
Who is sponsoring clinical trial NCT03472014?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03472014 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vaccination
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03472014's enrollment target sits among peer trials
22 12th of 12 higher than 1 of 12 other Vaccination trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Vaccination trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PFAS Exposure and Immune Response to Vaccination in Adults
COMPLETED · Phase 4
-
Can Stories Encourage the Elderly to Vaccinate? Combining Viewer-tailored Personal Narrative Videos With Informational Videos to Improve Vaccine Uptake Among Older Adults
RECRUITING · NA
-
"Facts Tell… and With Stories Sell?" Combining Viewer-tailored Personal Human Papillomavirus (HPV) Narrative Video With HPV Vaccine Information Video to Improve HPV Vaccine Uptake
RECRUITING · NA
-
ARISe at UMass Chan
RECRUITING · NA
-
Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases
RECRUITING
-
Kaiser Colorado Flu Nudge
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI